natgillin/translations-raw huggingface dataset:
diarré, kvalme, opkastning, påvirkning af mundslimhinden (f.eks. aftøs stomatit, mundsår), abdominalsmerter; colitis, herunder mikroskopisk colitis såsom lymfocytær colitis, kollagenøs colitis 
diarrhoea, nausea, vomiting, oral mucosal disorders (e.g., aphthous stomatitis, mouth ulceration), abdominal pain; colitis including microscopic colitis such as lymphocytic colitis, collagenous colitis
Efter 12 måneder med aktiv behandling var ACR responsraterne hos leflunomidpatienterne 52,3% (forsøg MN301/303), 50,5% (forsøg MN302) og 49,4% (forsøg US301) sammenlignet med 53,8% (forsøg MN301/303) hos sulfasalazinpatienterne, og henholdsvis 64,8% (forsøg MN302) og 43,9% (forsøg US301) hos methotrexatepatienterne. 
In the phase III trials, the ACR response rates for leflunomide 20 mg/day versus placebo were 54.6% vs. 28.6% (study MN301), and 49.4% vs. 26.3% (study US301).After 12 months with active treatment, the ACR response rates in leflunomide patients were 52.3% (studies MN301/303), 50.5% (study MN302) and 49.4% (study US301), compared to 53.8% (studies MN301/303) in sulphasalazine patients, 64.8% (study MN302), and 43.9% (study US301) in methotrexate patients.
Det anbefales, at patienter i leflunomidbehandling ikke behandles med kolestyramin eller aktivt kul, da det fremkalder et hurtig og markant fald i plasmakoncentrationen af A771726 (leflunomids aktive metabolit, se også pkt. 
It is recommended that patients receiving leflunomide are not treated with colestyramine or activated powdered charcoal because this leads to a rapid and significant decrease in plasma A771726 (the active metabolite of leflunomide; see also section 5) concentration.
I et mindre forsøg (n=30), hvor leflunomid (10-20 mg daglig) blev givet samtidig med methotrexate (10-25 mg ugentlig), sås en 2-3 gange forhøjelse af leverenzymer hos 5 ud af 30 patienter. 
In a small (n=30) study with co-administration of leflunomide (10 to 20 mg per day) with methotrexate (10 to 25 mg per week) a 2- to 3-fold elevation in liver enzymes was seen on 5 of 30 patients.
Leflunomide ratiopharm-behandlingen påbegyndes sædvanligvis med 100 mg daglig i de første 3 dage. 
The usual starting dosage of Leflunomide ratiopharm is 100 mg once daily for the first three days.
Ved dosisniveauet på20 mg/døgn er den gennemsnitlige plasmakoncentration af A771726 ved steady-state ca. 35 μg/ml. 
At a dose level of 20 mg/day, average plasma concentration of A771726 at steady state is approximately
Interstitial lungesygdom samt sjældne tilfælde af pulmonal hypertension er rapporteret under behandling med leflunomid (se pkt. 
Interstitial lung disease, as well as rare cases of pulmonary hypertension have been reported during treatment with leflunomide (see section 4.8).
• stigning i antallet af såkaldte eosinofile blodceller, et svagt fald i antallet af hvide blodlegemer 
- an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells
Leflunomide ratiopharm 10 mg filmovertrukne tabletter er hvide til næsten hvide og runde med en diameter på ca. 6 mm. 
Leflunomide ratiopharm 10 mg film-coated tablets are white to almost white and round with a diameter of about 6 mm.
Mandlige patienter bør være opmærksomme på mulighed for føtal toksicitet overført fra mandlig partner. 
Male patients should be aware of the possible male-mediated foetal toxicity.
Der findes pakningsstørrelser på 30 og 100 filmovertrukne tabletter pr. tabletglas. 
Pack sizes of 30 and 100 film-coated tablets per bottle are available.
Meget sjælden: svær leverskade som f.eks. leversvigt og akut hepatisk nekrose, som kan være fatal 
severe liver injury such as hepatic failure and acute hepatic necrosis that may be fatal
• Overfølsomhed (specielt tidligere Stevens-Johnson syndrom, toksisk epidermal nekrolyse, erythema multiforme) over for det aktive stof, den primære aktive metabolit teriflunomid, over for jordnødder eller soja eller over for et eller flere af hjælpestofferne anført i pkt. 
• Hypersensitivity (especially previous Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) to the active substance, to the principal active metabolite teriflunomide, to peanut or soya or to any of the excipients listed in section 6.1.
• Patienter med svær immundefekt, f.eks. aids 
• Patients with severe immunodeficiency states, e.g. AIDS,
Resultaterne fra studier af dyrefertilitet har ikke vist nogen virkning på fertiliteten hos hanner og hunner, men i toksicitetsførsøg med gentagen dosering er set bivirkninger på hanners reproduktionsorganer (se pkt. 
Results of animal fertility studies have shown no effect on male and female fertility, but adverse effects on male reproductive organs were observed in repeated dose toxicity studies (see section 5.3).
filmovertrukken tablet 30 filmovertrukne tabletter 100 filmovertrukne tabletter 
Film-coated tablet 30 film-coated tablets 100 film-coated tablets
• aktiv reumatoid artrit som et sygdomsmodificerende antireumatisk middel ("Disease 
• active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD).
Hver filmovertrukken tablet indeholder 76 mg lactose og 0,06 mg sojalecithin. 
Each film-coated tablet contains 76 mg of lactose and 0.06 mg of soya lecithin.
Åndedræts reaktioner 
Respiratory reactions
• Aktivt stof: Leflunomid. 
- The active substance is leflunomide.
Hver filmovertrukken tablet indeholder 152 mg lactose og 0,12 mg sojalecithin. 
Each film-coated tablet contains 152 mg of lactose and 0.12 mg of soya lecithin.
• nogle gange livstruende reaktioner (Steven-Johnson syndrom, toksisk epidermal nekrolyse, 
severe sometimes life-threatening reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme).
Indgift af en peroral suspension af aktivt kul eller kolestyramin til mennesker fører til en hurtig og markant øgning i eliminationen af A771726 og fald i plasmakoncentrationen (se pkt. 
It has been shown in man that administration of an oral suspension of activated powdered charcoal or colestyramine leads to a rapid and significant increase in A771726 elimination rate and decline in plasma concentrations (see section 4.9).
Folderen skal oplyse om dosisreduktion, seponering samt udvaskningsprocedure i situationer med forhøjet ALAT. 
The information provided in the Physician Leaflet should provide information on dose reduction, discontinuation and wash out procedures in the event of raised ALT.
• Øvrige indholdsstoffer: Lactosemonohydrat, lavsubstitueret hydroxypropylcellulose, vinsyre, natriumlaurylsulfat og magnesiumsterat i tabletkernen, såvel som lecithin (sojabønner), polyvinylalkohol, talcum, titandioxid (E171) og xanthangummi i filmovertrækket. 
- The other ingredients are lactose monohydrate, low-substituted hydroxypropyl cellulose, tartaric acid, sodium laurylsulfate and magnesium stearate in the tablet core as well as lecithin (soybeans) , poly(vinyl alcohol), talc, titanium dioxide (E171) and xanthan gum in the film-coating
De hyppigst rapporterede bivirkninger ved behandling med leflunomid er: mild blodtryksstigning, leukopeni, paræstesi, hovedpine, svimmelhed, diarré, kvalme, opkastning, påvirkniger i mundslimhinderne, (f.eks. aftøs stomatitis, mundsår), abdominalsmerter, øget hårtab, eksem, udslæt (inklusive maculopapulært udslæt), pruritus, tør hud, seneskedehindebetændelse, øget CPK, anoreksi, vægttab (sædvanligvis ubetydeligt), asteni, milde allergiske reaktioner og stigning i leverparametre (transaminaser særligt ALAT), mindre hyppigt gamma-GT, basisk fosfatase og bilirubin). 
The most frequently reported adverse effects with leflunomide are: mild increase in blood pressure, leucopenia, paraesthesia, headache, dizziness, diarrhoea, nausea, vomiting, oral mucosal disorders (e.g. aphthous stomatitis, mouth ulceration), abdominal pain, increased hair loss, eczema, rash (including maculo-papular rash), pruritus, dry skin, tenosynovitis, CPK increased, anorexia, weight loss (usually insignificant), asthenia, mild allergic reactions and elevation of liver parameters (transaminases (especially ALT), less often gamma-GT, alkaline phosphatise, bilirubin).
Pakningsstørrelser og yderligere oplysninger Leflunomide ratiopharm indeholder: 
Contents of the pack and other information What Leflunomide ratiopharm contains
Brug af anden medicin sammen med Leflunomide ratiopharm 
Other medicines and Leflunomide ratiopharm
Leflunomide ratiopharm 20 mg filmovertrukne tabletter er hvide til næsten hvide og runde med en diameter på ca. 8 mm og en delekærv på den ene side af tabletten. 
Leflunomide ratiopharm 20 mg film-coated tablets are white to almost white and round with a diameter of about 8 mm and a break-mark on one side of the tablet.
ratiopharm Oy Puh/Tel: +358 20 180 5900 
Suomi/Finland ratiopharm Oy Puh/Tel: +358 20 180 5900
• 1 tablet på 10 eller 20 mg Leflunomide ratiopharm daglig til behandling af aktiv leddegigt afhængig af sygdommens alvorlighed. 
• For rheumatoid arthritis: 10 or 20 mg Leflunomide ratiopharm once daily, depending on the severity of the disease.
Merckle GmbH Ludwig-Merckle-Str. 3 89143 Blaubeuren Tyskland 
Merckle GmbH Ludwig-Merckle-Str. 3 89143 Blaubeuren Germany
Samtidig anvendelse af leflunomid og antimalariamidler, som benyttes ved rheumatiske sygdomme (f.eks. klorokin og hydroxyklorokin), intramuskulært eller peroralt guld, D-penicillamin, azathioprin og andre immunosuppressive lægemidler, inklusive tumor nekrosis factor alfa-hæmmere er på nuværende tidspunkt ikke tilstrækkeligt undersøgt i randomiserede forsøg (dog undtaget methotrexat, se pkt. 
The use of leflunomide with antimalarials used in rheumatic diseases (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive agents including Tumour Necrosis Factor alpha-Inhibitors has not been adequately studied up to now in randomised trials (with the exception of methotrexate, see section 4.5).
pancytopeni skal Leflunomide ratiopharm og anden samtidig behandling med myelosuppresive lægemidler seponeres og leflunomid udvaskningsproceduren påbegyndes. 
In case of severe haematological reactions, including pancytopenia, Leflunomide ratiopharm and any concomitant myelosuppressive treatment must be discontinued and a leflunomide washout procedure initiated.
• Patienter med nedsat leverfunktion 
• Patients with impairment of liver function.
EU/1/10/654/003 30 filmovertrukne tabletter EU/1/10/654/004 100 filmovertrukne tabletter 
EU/1/10/654/003 30 film-coated tablets EU/1/10/654/004 100 film-coated tablets
EU/1/10/654/001 30 filmovertrukne tabletter EU/1/10/654/002 100 filmovertrukne tabletter 
EU/1/10/654/001 30 film-coated tablets EU/1/10/654/002 100 film-coated tablets
• smagsforstyrrelser, 
taste disturbances
I forsøg MN302 blev 999 forsøgspersoner med aktiv reumatoid artrit randomiseret til leflunomid 20 mg daglig (n = 501) eller methotrexate 7,5 mg ugentlig stigende til 15 mg ugentlig (n = 498). 
Study MN302 randomised 999 subjects with active rheumatoid arthritis to leflunomide 20 mg/day (n=501) or methotrexate at 7.5 mg/week increasing to 15 mg/week (n=498).
Lægen kan tilråde at stoppe med at tage Leflunomide ratiopharm og tage bestemte typer medicin, der kan udrense Leflunomide ratiopharm fra kroppen hurtigt og tilstrækkeligt. 
Men wishing to father a child should contact their doctor who may advise them to stop taking Leflunomide ratiopharm and take certain medicines to remove Leflunomide ratiopharm rapidly and sufficiently from their body.
• Patienter med svær hypoproteinæmi, f.eks. ved nefrotisk syndrom 
• Patients with severe hypoproteinaemia, e.g. in nephrotic syndrome.
I forsøg US301 blev 482 forsøgspersoner med aktiv reumatoid artrit randomiseret til leflunomid 20 mg daglig (n = 182), methotrexate 7,5 mg ugentlig stigende til 15 mg ugentlig (n = 182), eller placebo (n = 118). 
Study US301 randomised 482 subjects with active rheumatoid arthritis to leflunomide 20 mg/day (n=182), methotrexate 7.5 mg/week increasing to 15 mg/week (n=182), or placebo (n=118).
Leflunomide ratiopharm indeholder lactose. 
Leflunomide ratiopharm contains lactose.
Desuden skal der fremsendes en opdateret RMP når der modtages nye oplysninger, der kan have indflydelse på den gældende sikkerhedsspecifikation, lægemiddelovervågningsplan eller risikominimeringsaktiviteter Senest 60 dage efter en vigtig milepæl er nået (lægemiddelovervågning eller risikominimering) på anmodning fra det Europæiske Lægemiddelagentur 
• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE TABLETGLAS 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Bottle
Kontakt lægen, apoteket eller sundhedspersonalet før du tager Leflunomide ratiopharm 
Talk to your doctor, pharmacist or nurse before taking Leflunomide ratiopharm - if you have ever suffered from interstitial lung disease.
Da det ikke kan udelukkes, at Leflunomide ratiopharm findes i sæden, skal der bruges pålidelig prævention under behandlingen med Leflunomide ratiopharm. 
- if you are male and wish to father a child. As it can not be excluded that Leflunomide ratiopharm passes into semen, reliable contraception should be used during treatment with Leflunomide ratiopharm.
Indehaveren af markedsføringstilladelsen ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Tyskland 
Marketing Authorisation Holder ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany
Efter 16 ugers behandling var forskellen i responsraterne statistisk signifikant til methotrexates fordel til børnegigt ”definition of improvement (DOI)” ≥30 % (p=0,02 %). 
In this trial, the loading dose and maintenance dose of leflunomide was based on three weight categories: <20 kg, 20-40 kg, and >40 kg. After 16 weeks treatment, the difference in response rates was statistically significant in favour of methotrexate for the JRA Definition of Improvement (DOI) ≥30% (p=0.02).
Er du i tvivl, så spørg lægen eller på apoteket. 
- If you have any further questions, ask your doctor,pharmacist or nurse.
Leflunomide ratiopharm indeholder lactose 
Leflunomide ratiopharm contains lactose
• hvis du får udslæt, eller mundsår, da disse kan være tegn på alvorlige, nogle gange livstruende reaktioner (f.eks. Steven-Johnson syndrom, toksisk epidermisk nekrolyse, erythema multiforme, lægemiddelreaktion med eosinofili og systemiske symptomer [DRESS]), se pkt. 
Tell your doctor immediately and stop taking Leflunomide ratiopharm: if you experience weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic reaction, if you develop a skin rash or ulcers in your mouth, as these may indicate severe, sometimes life-threatening reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]), see section 2.
Tel: +31 (0)800 0228 400 
Teva Nederland B.V. Tel: +31 (0) 800 0228 400
Det skal du vide, før du begynder at tage Leflunomide ratiopharm Sådan skal du tage Leflunomide ratiopharm Bivirkninger 
What Leflunomide ratiopharm is and what it is used for What you need to know before you take Leflunomide ratiopharm How to take Leflunomide ratiopharm Possible side effects
Sådan skal du tage Leflunomide ratiopharm 
How to take Leflunomide ratiopharm
Nyrer og urinveje Ikke kendt: nyresvigt 
Renal and urinary disorders Not known:
Indlægsseddel: Information til brugeren Leflunomide ratiopharm 10 mg filmovertrukne tabletter leflunomid 
Package leaflet: Information for the user Leflunomide ratiopharm 10 mg film-coated tablets
Hver tablet indeholder 20 mg leflunomid. 
Each tablet contains 20 mg of leflunomide.
Indlægsseddel: Information til brugeren Leflunomide ratiopharm 20 mg filmovertrukne tabletter leflunomid 
Package leaflet: Information for the user Leflunomide ratiopharm 20 mg film-coated tablets
hypourikæmi 
hypouricemia
Alanin-aminotransferase (ALAT) eller serum-glutamopyruvattransferase (SGPT) og det fulde blodbillede inklusive leukocytdifferentialtælling og trombocyttal skal kontrolleres samtidigt med og med samme hyppighed: 
Alanine aminotransferase (ALT) or serum glutamopyruvate transferase (SGPT) and a complete blood cell count, including a differential white blood cell count and a platelet count, must be checked simultaneously and with the same frequency: before initiation of leflunomide, every two weeks during the first six months of treatment, and every 8 weeks thereafter (see section 4.4).
For at få mere information om dette, skal du læse pkt. 
For more information on these, please read section 4 (Possible side effects).
Hver tablet indeholder 10 mg leflunomid. 
Each tablet contains 10 mg of leflunomide.
• blodprøver kan vise en forhøjelse af nogle leverresultater som kan føre til alvorlige tilstande såsom leverbetændelse og gulsot, alvorlige infektioner (blodforgiftning), som kan være livstruende, 
(pancytopenia), - severe increase in blood pressure, - inflammation of the lung (interstitial lung disease), - an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice, - severe infections called sepsis which may be fatal, - an increase of certain enzymes in the blood (lactate dehydrogenase).
Da eventuelle leverskader forvoldt af alkohol kan forværres af behandling med Leflunomide ratiopharm, anbefales det ikke at drikke alkohol under behandling med Leflunomide ratiopharm. 
It is not recommended to drink alcohol during treatment with Leflunomide ratiopharm.
Leflunomide ratiopharm 10 mg tabletter leflunomid 
Leflunomide ratiopharm 10 mg tablets Leflunomide
Leflunomide ratiopharm 20 mg tabletter leflunomid 
Leflunomide ratiopharm 20 mg tablets Leflunomide
Psykiske forstyrrelser Ikke almindelig: angst 
Psychiatric disorders Uncommon:
Ikke almindelig: anæmi, let trombocytopeni (trombocytter < 100 G/l) Sjælden: 
anaemia, mild thrombocytopenia (platelets <100 G/L)
• hvis du nogensinde har haft en allergisk reaktion over for leflunomide (specielt en alvorlig hudreaktion, ofte ledsaget af feber, ledsmerter, røde pletter på huden eller blærer, f.eks. Stevens-Johnson syndrom), over for jordnødder eller soja eller et af de øvrige indholdsstoffer i Leflunomide ratiopharm (angivet i pkt. 
What you need to know before you take Leflunomide ratiopharm Do not take Leflunomide ratiopharm if you have ever had an allergic reaction to leflunomide (especially a serious skin reaction, often accompanied by fever, joint pain, red skin stains, or blisters e.g. Stevens-Johnson syndrome), to peanut or soya or to any of the other ingredients of this medicine (listed in section if you have any liver problems, if you have moderate to severe kidney problems, if you have severely low numbers of proteins in your blood (hypoproteinaemia), if you suffer from any problem which affects your immune system (e.g. AIDS), if you have any problem with your bone marrow, or if you have low numbers of red or white cells in your blood or a reduced number of blood platelets, if you are suffering from a serious infection, if you are pregnant, think you may be pregnant, or are breast-feeding.
Ikke almindelige bivirkninger (kan påvirke op til 1 ud af 10 ud af 100 personer) 
Uncommon side effects (may affect up to 1 in 100 people)
Ikke kendt pulmonal hypertension 
pulmonary hypertension Gastrointestinal disorders Common:
Hver filmovertrukken tablet indeholder 10 mg leflunomid. 
Each film-coated tablet contains 10 mg of leflunomide.
• En filmovertrukken tablet indeholder 20 mg leflunomid. 
One film-coated tablet contains 20 mg of leflunomide.
Leflunomide ratiopharm 10 mg filmovertrukne tabletter leflunomid 
Leflunomide ratiopharm 10 mg film-coated tablets Leflunomide
Leflunomide ratiopharm 20 mg filmovertrukne tabletter leflunomid 
Leflunomide ratiopharm 20 mg film-coated tablets Leflunomide
• 1 tablet på 20 mg Leflunomide ratiopharm daglig til behandling af gigt i forbindelse med psoriasis. 
• For psoriatic arthritis: 20 mg Leflunomide ratiopharm once daily.
Leflunomide ratiopharm 10 mg filmovertrukken tablet 
Leflunomide ratiopharm 10 mg film-coated tablets
Leflunomide ratiopharm indeholder sojalecithin. 
Leflunomide ratiopharm contains soya lecithin
Natriumlaurylsulfat 
Sodium laurylsulfate Magnesium stearate
Leflunomide ratiopharm 20 mg filmovertrukken tablet 
Leflunomide ratiopharm 20 mg film-coated tablets
Hvis du har taget for meget Leflunomide ratiopharm 
If you take more Leflunomide ratiopharm than you should
• fald i antallet af røde blodlegemer (anæmi) og fald i antallet af blodplader (trombocytopeni), 
a decrease in the number of red blood cells (anaemia) and a decrease in the number of blood platelets (thrombocytopenia), - a decrease in the levels of potassium in the blood, - anxiety, - taste disturbances, - urticaria (nettle rash), - tendon rupture, - an increase in the levels of fat in the blood (cholesterol and triglycerides), - a decrease in the levels of phosphate in the blood.
• teriflunomid mod dissemineret sklerose 
• Physician Leaflet
• hovedpine, svimmelhed, 
Hepatic impairment
Indhold Pakningsstørrelser 
Packaging Content Package size
EU Nummer Produktnavn 
EU Number
Fiskeolie 0,5 ml/ml 
Fish Oil 0.5ml/Ml
Fiskeolie 1.000-mgkapsel 
Fish Oil 1000mg Capsule
Omega-3syreethylestere 90 med en specifik sammensætning af EPA og DHA ikke lavere end 85 % 500-mg-kapsel 
Omega-3-Acid Ethyl Esters 90 With A Specific Composition For Epa And Dha Not Lower Than 85%.
1.000-mg-kapsel 
1000mg Capsule
Ratiopharm Gmbh Omega-3 Ratiopharm Omega-3syreethylestere 90 
Ratiopharm Gmbh Omega-3 Ratiopharm Omega-3-Acid Ethyl Esters 90 1000mg
Omega-3-fedtsyrer 1.000-mg-kapsel 
Omega-3 Fatty Acids 1000mg Capsule
Ácidos Omega 3 Aristo Omega-3syreethylestere 1.000mg-kapsel 
Ácidos Omega 3 Aristo Omega-3-Acid Ethyl Esters 1000mg Capsule
1 000-mg-tablet 
1000mg
Triglycerider med middel kædelængde 1qs-kapsel, sojalecithin 1-qs-kapsel, Omega-3syreethylestere 90 
Triglycerides Medium Chain 1qs Capsule, Lecithin Soya 1qs Capsule, Omega-3-Acid Ethyl Esters 90 1000mg Capsule
Docosahexaensyre 60mg-kapsel, eicosapentaensyre 90mg-kapsel 
Docosahexaenoic Acid 60mg Capsule, Eicosapentaenoic Acid 90mg Capsule
Estere af umættede fedtsyrer 500-mgkapsel 
Esters Of Unsaturated Fatty Acids 500mg Capsule
Docosahexaensyre 265mg/5 ml, eicosapentaensyre 390mg/5 ml 
Docosahexaenoic Acid 265mg/5ml, Eicosapentaenoic Acid 390mg/5ml
Estere af umættede fedtsyrer 1.000-mgkapsel 
Esters Of Unsaturated Fatty Acids 1000mg Capsule
Docosahexaensyre 120mg-kapsel, eicosapentaensyre 180mg-kapsel 
Docosahexaenoic Acid 120mg Capsule, Eicosapentaenoic Acid 180mg Capsule
Docosahexaensyre 115mg-kapsel, eicosapentaensyre 170mg-kapsel 
Docosahexaenoic Acid 115mg Capsule, Eicosapentaenoic Acid 170mg Capsule
Eicosapentaensyreethyl ester 430-mg-kapsel, docosahexaensyreethyle ster 437-mg-kapsel 
Docosahexaenoic Acid Ethyl Ester 437mg Capsule
Ácidos Omega 3 Tarbis Docosahexaensyre 380mg-kapsel, eicosapentaensyre 460mg-kapsel, omega-3syreethylestere 90 
Ácidos Omega 3 Tarbis Docosahexaenoic Acid 380mg Capsule,
Docosahexaensyre 115mg-kapsel, eicosapentaensyre/doco sahexaensyre 170-mgkapsel 
Docosahexaenoic Acid 115mg Capsule, Eicosapentanoic Acid/Docosahexaenoic Acid 170mg Capsule
Docosahexaensyre 527 mg/5 ml, eicosapentaensyre/doco sahexaensyre 791 mg/5 ml 
Docosahexaenoic Acid 527mg/5ml, Eicosapentanoic Acid/Docosahexaenoic Acid 791mg/5ml
Acidos Omega 3 Stada Omega-3syreethylestere 90 
Acidos Omega 3 Stada Omega-3-Acid Ethyl Esters 90 1000mg
Docosahexaensyre 527 mg/5 ml, eicosapentaensyre 791 mg/5 ml 
Docosahexaenoic Acid 527mg/5ml, Eicosapentaenoic Acid 791mg/5ml
Docosahexaensyre 115mg-kapsel, D-vitamin 1 IE/g, eicosapentaensyre 170-mg-kapsel, Avitamin 1 IE/g 
Docosahexaenoic Acid 115mg Capsule, Vitamin D 1 I.U.G,
Eicosapentaensyreethyl ester 460-mg-kapsel, docosahexaensyreethyle ster 380-mg-kapsel 
Docosahexaenoic Acid Ethyl Ester 380mg Capsule
Eicosapentaensyre 115mg-kapsel, D-vitamin 10 IE/g, docosahexaensyre 170mgkapsel, A-vitamin 100 IE/g 
Eicosapentaenoic Acid 170mg Capsule, Vitamin A 100 I.U.G
Docosahexaensyre 527 mg/5 ml, D-vitamin 10 IE/g, eicosapentaensyre 791 mg/5 ml, A-vitamin 100 IE/g 
Eicosapentaenoic Acid 791mg/5ml, Vitamin A 100 I.U.G